Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Baxter
Express Scripts
AstraZeneca
McKesson

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for LY3039478

See Plans and Pricing

« Back to Dashboard

What is the drug development status for LY3039478?

LY3039478 is an investigational drug.

There have been 8 clinical trials for LY3039478. The most recent clinical trial was a Phase 1 trial, which was initiated on September 1st 2015.

The most common disease conditions in clinical trials are Leukemia, Lymphoid, Neoplasms, Plasma Cell, and Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, Fred Hutchinson Cancer Research Center, and National Cancer Institute (NCI).

There are six US patents protecting this investigational drug and ninety-seven international patents.

Recent Clinical Trials for LY3039478
TitleSponsorPhase
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple MyelomaNational Cancer Institute (NCI)Phase 1
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple MyelomaFred Hutchinson Cancer Research CenterPhase 1
A Study of LY3039478 in Participants With Advanced or Metastatic Solid TumorsEli Lilly and CompanyPhase 1

See all LY3039478 clinical trials

Clinical Trial Summary for LY3039478

Top disease conditions for LY3039478
Top clinical trial sponsors for LY3039478

See all LY3039478 clinical trials

US Patents for LY3039478

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
LY3039478   Start Trial Combinations of LSD1 inhibitors for use in the treatment of solid tumors Oryzon Genomics, S.A. (Madrid, ES)   Start Trial
LY3039478   Start Trial Notch pathway signaling inhibitor compound Eli Lilly and Company (Indianapolis, IN)   Start Trial
LY3039478   Start Trial ERK inhibitors Eli Lilly and Company (Indianapolis, IN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Colorcon
Dow
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.